Skip to content

The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine

The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07131826
Enrollment
200
Registered
2025-08-20
Start date
2025-08-15
Completion date
2026-12-31
Last updated
2025-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS, Cabotegravir, Quality of Life, Rilpivirine, Viral Control

Keywords

cabotegravir, rilpivirine, AIDS, quality of life, viral control

Brief summary

AIDS was once regarded as the Black Death of the 20th century. However, with the advent of cocktail therapy, the survival rate of infected people has been greatly improved and the average life expectancy has been increased. Today, AIDS is considered a chronic disease, just like hypertension and diabetes. As long as you have regular checkups and take medication on time every day, you can complete the treatment, just like a normal person. However, there is still a risk of missing medication when taking it every day, and long-term missed medications can easily lead to drug resistance and increase the risk of treatment failure. After the HIV-infected person has stabilized the viral load, their mobility, self-care and daily activities are no different from those of normal people. However, they experience side effects such as fatigue, lack of energy, difficulty sleeping, depression, changes in appearance, tension and anxiety, dizziness, headache, vomiting, etc., which affect their quality of life. The long-acting AIDS injection is a long-acting dosage form for intramuscular injection. It has been included in the national health insurance reimbursement standards. Treatment with long-acting injections can reduce the risk of infected people forgetting to take medicine, and there is no need to worry about the exposure of the disease when storing the medicine. Through this study, we hope to collect the results of long-acting injections for stable HIV treatment cases (health status, daily activities, injection site, satisfaction), and confirm that long-acting injections can significantly improve the quality of daily life of HIV-infected people.

Interventions

Observational study, non-interventional

Sponsors

National Taiwan University Hospital
CollaboratorOTHER
National Taiwan University Clinical Trial Center
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

18 years and above Clinical diagnosis of HIV infection completed long-acting injectable treatment Accept the questionnaire

Exclusion criteria

Not clinical diagnosis of HIV infection Do not accept questionnaires

Design outcomes

Primary

MeasureTime frame
To whether long-acting injections can significantly improve the quality of daily life of people infected with HIV using a questionnaireFrom the date of approval by the CTC to December 31, 2026.

Countries

Taiwan

Contacts

Primary ContactWANG-HUEI SHENG
ntuhrec@ntuh.gov.tw+886-02-2312-3456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026